{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007036","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.446546+00:00","generated_at":"2026-06-18T06:12:28.987305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iridex Q4 revenue flat at $15.2M; record glaucoma probe sales; FY net loss widens to $7.5M","bullets":["Q4 revenue $15.2M (flat YoY); net loss improved to $1.1M ($0.07/sh) from $2.4M loss.","FY2022 revenue $57.0M (+6% YoY); net loss $7.5M ($0.47/sh) vs $5.2M ($0.34) in 2021.","Record Cyclo G6 probe sales: 16,400 units in Q4 (+8% YoY); Q4 glaucoma product revenue $4.2M (+9%).","Retina revenue $8.1M in Q4 (-11% YoY); full-year retina $31.7M (+2%).","2023 guidance: revenue $57-59M; Cyclo G6 probes 65k-67k units (9-12% growth); adjusting for ~$1.5M royalty reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007036","json":"https://secwatch.observer/filing/0000950170-23-007036.json","markdown":"https://secwatch.observer/filing/0000950170-23-007036.md","text":"https://secwatch.observer/filing/0000950170-23-007036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/irix-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:12:28.987305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5536be9a10abc45e4262940ad79bc98c7623856","claim":"IRIDEX CORP reported the three months ended December 31, 2022 results: revenue $15.2 million, net income $1.1 million, EPS $0.07 per share.","evidence_excerpt":"results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance. Fourth Quarter 2022 & Recent Highlights • Generated total revenue of $15.2 million, essentially unchanged from the prior year period • Cyclo G6® product family revenue of $4.2 million, an increase of 9% year-over-year o 16,400 Cyclo G6 probes sold, a quarterly","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$15.2 million"},{"label":"Net income","value":"$1.1 million"},{"label":"EPS","value":"$0.07 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e066b930c734f9e3c59a0df5ffc634a5778e20cf","claim":"IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance initiated.","evidence_excerpt":"Total revenue for the full year is expected to be $57 million to $59 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$57 million to $59 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e4fbcf7dd8489ad444a56480ec79b44072a05aad","claim":"IRIDEX CORP reported the year ended December 31, 2022 results: revenue $57.0 million, net income $7.5 million, EPS $0.47 per share.","evidence_excerpt":"577 systems in February 2023 • Cash and cash equivalents totaled approximately $13.9 million as of December 31, 2022 Full Year 2022 Highlights • Generated total revenue of $57.0 million, an increase of 6% compared to 2021 • Cyclo G6 product family revenue of $14.7 million, an increase of 5% year-over-year • Sold 59,800 Cyclo G6 probes, compared to 58,200 in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017023007036/0000950170-23-007036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$57.0 million"},{"label":"Net income","value":"$7.5 million"},{"label":"EPS","value":"$0.47 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}